Drug, ad firms gird as House takes up FDA revamp
Pharmaceutical and advertising industry lobbyists who thwarted attempts in the Senate to rein in drug advertising now turn their attention to the House of Representatives, which is scheduled to take up legislation to overhaul the Food and Drug Administration today. (Full article: 611 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
